RE
ADCT icon

RBC Europe’s ADC Therapeutics ADCT Stock Holding History

RBC Europe’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-115
Closed -$3.12K – 634
2021
Q3 		$3.12K Hold
115
– – ﹤0.01% 1091
2021
Q2 		$2.8K Hold
115
– – ﹤0.01% 1094
2021
Q1 		$2.81K Buy
+115
New +$3.33K ﹤0.01% 1049

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RBC Europe's ADCT Position: Q4 2021 in Review

RBC Europe sold out of ADC Therapeutics (ADCT) in Q4 2021, closing a stake of 115 shares — an estimated $3.12K sold.

RBC Europe first reported a position in ADCT in Q1 2021 and held it in 3 quarters. The position peaked at $3.12K in Q3 2021. 55 funds tracked by Wall St. Rank hold ADCT as of Q4 2021.

  • RBC Europe reported no remaining ADC Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 115 ADC Therapeutics shares in Q4 2021, an estimated $3.12K.
  • RBC Europe first reported a position in ADC Therapeutics in Q1 2021 and held it in 3 quarters.
  • RBC Europe's ADC Therapeutics position peaked at $3.12K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.